Home
Storia in 4 fonti
Parkinson’s drug from Biogen, Denali comes up short
High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
- ·
markets.businessinsider.com
Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints
Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small...
- ·
statnews.com
Closely watched experimental Parkinson’s drug fails key clinical trial
Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.
